Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 14/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316361 | 1.00 | KDM4E (0.47) | KDM4EPKMTGFBR1USP30ST14 | |
| SCHEMBL6318034 | 0.85 | KDM4E (0.46) | KDM4EPKMTGFBR1YAP1 | |
| SCHEMBL6326438 | 0.83 | CHRM3 (0.41) | ST14KDM1A | |
| SCHEMBL6326432 | 0.83 | CHRM3 (0.41) | ST14KDM1A | |
| SCHEMBL6130337 | 0.79 | F10 (0.51) | ST14 | |
| SCHEMBL14744625 | 0.77 | KDM4E (0.52) | KDM4EPKMTGFBR1USP30YAP1 | |
| SCHEMBL6831986 | 0.77 | KDM4E (0.48) | KDM4EPKMTGFBR1USP30YAP1 | |
| SCHEMBL17982809 | 0.74 | KDM4E (0.56) | KDM4EPKMTGFBR1YAP1 | |
| SCHEMBL7038825 | 0.73 | NOTCH1 (0.44) | KDM4EPKMTGFBR1YAP1 | |
| SCHEMBL1532753 | 0.73 | KDM4E (0.55) | KDM4EPKMTGFBR1YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101675-A1 | Benzamidine derivatives and process for production thereof | TEIJIN LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1357108-A1 | BENZAMIDINE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | TEIJIN LIMITED (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101675-A1 | Benzamidine derivatives and process for production thereof | AOC2, TALDO1, AOC1 | KDM4E 3010/4885PKM 329/4885TGFBR1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.